Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes by Seino, Yutaka et al.
Title
Safety and efficacy of semaglutide once weekly vs sitagliptin
once daily, both as monotherapy in Japanese people with type 2
diabetes
Author(s)
Seino, Yutaka; Terauchi, Yasuo; Osonoi, Takeshi; Yabe,
Daisuke; Abe, Nobuyuki; Nishida, Tomoyuki; Zacho, Jeppe;
Kaneko, Shizuka




© 2017 The Authors.Diabetes, Obesity and Metabolism
published by John Wiley & Sons Ltd. This is an open access
article under the terms of the Creative Commons Attribution‐
NonCommercial‐NoDerivs License, which permits use and
distribution in any medium, provided the original work is
properly cited, the use is non‐commercial and no




OR I G I N A L A R T I C L E
Safety and efficacy of semaglutide once weekly vs sitagliptin
once daily, both as monotherapy in Japanese people with type
2 diabetes
Yutaka Seino MD, PhD1,2 | Yasuo Terauchi MD, PhD3 | Takeshi Osonoi MD, PhD4 |
Daisuke Yabe MD, PhD1,2,5 | Nobuyuki Abe MD6 | Tomoyuki Nishida MSc7 |
Jeppe Zacho MD, PhD7 | Shizuka Kaneko MD, PhD8
1Kansai Electric Power Medical Research
Institute, Kobe, Japan
2Kansai Electric Power Hospital, Osaka, Japan
3Yokohama City University, Yokohama, Japan
4Naka Memorial Clinic, Ibaraki, Japan
5Kyoto University, Kyoto, Japan
6Abe Clinic, Oita, Japan
7Novo Nordisk Pharma Ltd, Tokyo, Japan
8Takatsuki Red Cross Hospital, Osaka, Japan
Correspondence
Yutaka Seino, MD, PhD, Kansai Electric Power
Hospital, 553-0003 Osaka Prefecture, Osaka,




This trial was supported by Novo Nordisk A/S;
NCT02254291.
Aims: To assess the safety and efficacy of monotherapy with once-weekly subcutaneous (s.c.)
semaglutide vs sitagliptin in Japanese people with type 2 diabetes (T2D).
Methods: In this phase IIIa randomized, open-label, parallel-group, active-controlled, multicen-
tre trial, Japanese adults with T2D treated with diet and exercise only or oral antidiabetic drug
monotherapy (washed out during the run-in period) received once-weekly s.c. semaglutide (0.5
or 1.0 mg) or once-daily oral sitagliptin 100 mg. The primary endpoint was number of
treatment-emergent adverse events (TEAEs) after 30 weeks.
Results: Overall, 308 participants were randomized and exposed to treatment, with similar
baseline characteristics across the groups. In total, 2.9% of participants in both the semaglutide
0.5 mg and the sitagliptin group prematurely discontinued treatment, compared with 14.7% in
the semaglutide 1.0 mg group. The majority of discontinuations in the semaglutide 0.5 and
1.0 mg groups were attributable to adverse events (AEs). More TEAEs were reported in
semaglutide- vs sitagliptin-treated participants (74.8%, 71.6% and 66.0% in the semaglutide
0.5 mg, semaglutide 1.0 mg and sitagliptin groups, respectively). AEs were mainly mild to mod-
erate. Gastrointestinal AEs, most frequently reported with semaglutide, diminished in frequency
over time. The mean glycated haemoglobin (HbA1c [baseline 8.1%]) decreased by 1.9% and
2.2% with semaglutide 0.5 and 1.0 mg, respectively, vs 0.7% with sitagliptin (estimated treat-
ment difference [ETD] vs sitagliptin −1.13%, 95% confidence interval [CI] −1.32; −0.94, and
−1.44%, 95% CI −1.63; −1.24; both P < .0001). Body weight (baseline 69.3 kg) was reduced by
2.2 and 3.9 kg with semaglutide 0.5 and 1.0 mg, respectively (ETD −2.22 kg, 95% CI −3.02;
−1.42 and −3.88 kg, 95% CI −4.70; −3.07; both P < .0001).
Conclusions: In Japanese people with T2D, more TEAEs were reported with semaglutide than
with sitagliptin; however, the semaglutide safety profile was similar to that of other glucagon-
like peptide-1 receptor agonists. Semaglutide significantly reduced HbA1c and body weight
compared with sitagliptin.
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1 | INTRODUCTION
The prevalence of type 2 diabetes (T2D) and prediabetes increased
significantly from the 1980s to the 2000s in the Japanese population,
with increasing obesity and declining physical activity.1
Achieving glycated haemoglobin (HbA1c) targets is a challenge
for many patients with T2D.2 Avoidance of weight gain and hypogly-
caemia are important considerations in selecting appropriate treat-
ment and individualizing treatment goals.3,4 Unlike most other T2D
therapies, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs)
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can achieve glycaemic control and reduce body weight, with a low
risk of hypoglycaemia.5
Semaglutide is a GLP-1 analogue in development for the treat-
ment of T2D, with a 94% homology to native GLP-1.6 A half-life of
~1 week makes it appropriate for once-weekly administration.6,7
Sitagliptin, a once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor,
is a widely used oral antidiabetic drug (OAD), and the most commonly
used DPP-4 inhibitor in Japan.8 DPP-4 inhibitors achieve glycaemic
control by inhibiting DPP-4-dependent inactivation of both GLP-1
and gastric inhibitory polypeptide (GIP), thereby enhancing GLP-1
and GIP receptor signalling, and thus are distinct from GLP-1 RAs,
which stably activate GLP-1 receptor signalling.9
Semaglutide has been evaluated in the “Semaglutide Unabated
Sustainability in Treatment of Type 2 Diabetes” (SUSTAIN) pro-
gramme, consisting of six phase III global clinical trials that evaluated
the efficacy and safety (including cardiovascular outcomes) of sema-
glutide vs a range of comparators, including sitagliptin.10–15 Two
additional phase III clinical trials in the SUSTAIN programme investi-
gated the effect of semaglutide in Japanese populations.16,17
In the present trial we evaluated the safety and efficacy of
30 weeks of treatment with once-weekly semaglutide (0.5 and
1.0 mg) vs once-daily sitagliptin (100 mg), both as monotherapy, in
Japanese adults with T2D who were previously stable on diet/exer-
cise or OAD monotherapy.17
2 | MATERIALS AND METHODS
2.1 | Trial design
This was a phase III randomized (1:1:1), open-label, parallel-group,
active-controlled, single-country (Japan), multicentre trial
(NCT02254291; Figure S1). This trial was conducted to meet the
“Guideline for Clinical Evaluation of Oral Hypoglycaemic Agents”
issued by the Japanese Ministry of Health, Labour and Welfare,18
which advises that new drugs are assessed as monotherapy to inves-
tigate their isolated effects. A specific comparator is not stipulated in
the guideline; however, sitagliptin was chosen as an active compara-
tor because it is widely available in Japan,8 and has a well-known effi-
cacy and safety profile. The trial was conducted in compliance with
the International Conference on Harmonisation Good Clinical Prac-
tice guidelines19 and the Declaration of Helsinki.20 Written informed
consent was obtained from all participants.
2.2 | Trial population
Japanese men and women were eligible for inclusion if they were
aged ≥20 years, diagnosed with T2D, and treated with either diet
and exercise therapy in addition to OAD monotherapy if their HbA1c
levels were 6.5% to 9.5% (48–80 mmol/mol; hereafter called OAD
monotherapy), or treated with diet and exercise therapy only if their
HbA1c levels were 7.0% to 10.5% (53–91 mmol/mol) for at least
30 days before screening.
Key exclusion criteria were: treatment with glucose-lowering
agents (except for pre-trial OAD in participants treated with OAD
monotherapy) in the 60 days before screening (except for short-term
use of insulin in connection with intercurrent illness of ≤7 days); his-
tory of chronic or idiopathic acute pancreatitis; screening calcitonin
value ≥50 ng/L; personal or family history of medullary thyroid carci-
noma or multiple endocrine neoplasia syndrome type 2; impaired
renal function (estimated glomerular filtration rate < 60 mL/min/
1.73 m2 per modification of diet in renal disease formula [4-variable
version]); acute coronary or cerebrovascular event within 90 days
before randomization; or heart failure, New York Heart Association
class IV. Full inclusion and exclusion criteria are listed in Table S1.
2.3 | Randomization and masking
Participants were randomly assigned using an interactive voice/web
response system in a 1:1:1 ratio to receive once-weekly subcutane-
ous (s.c.) semaglutide (0.5 or 1.0 mg) or once-daily oral sitagliptin
100 mg. Randomization was stratified according to pre-trial treat-
ment at screening (diet and exercise therapy or OAD monotherapy).
2.4 | Drug administration
After an 8-week washout (OAD monotherapy group) or 2-week
screening period (diet and exercise only group), participants received
s.c. semaglutide 0.5 or 1.0 mg once weekly or sitagliptin 100 mg once
daily for 30 weeks, followed by a 5-week follow-up period
(Figure S1). Participants in the semaglutide arms followed a fixed
dose-escalation regimen of semaglutide 0.5 mg (maintenance dose
reached after 4 weeks of 0.25 mg semaglutide once weekly) or sema-
glutide 1.0 mg (maintenance dose reached after 4 weeks of 0.25 mg
semaglutide, followed by 4 weeks of 0.5 mg semaglutide).
In case of a safety concern or unacceptable intolerability, the trial
product could be discontinued at the investigator’s discretion and
was not to be reinitiated. Participants discontinuing trial product pre-
maturely were asked to continue with the scheduled site contact
(if necessary, in order to retain the participant in the trial, site visits
were replaced by phone contacts after discontinuation) and, as a min-
imum, were asked to attend the visits for end of treatment and
follow-up at the time of the scheduled completion of the trial.
2.5 | Trial endpoints and assessments
The primary endpoint was the number of treatment-emergent
adverse events (TEAEs) during 30 weeks of treatment.
Supportive secondary efficacy endpoints included change from
baseline to week 30 in: HbA1c; fasting plasma glucose (FPG); self-
measured plasma glucose (SMPG [measurements performed with
capillary blood were automatically calibrated to plasma-equivalent
glucose values, shown on the display of the blood glucose (BG) meter
and documented by the trial participant]; mean 7-point profile and
mean postprandial increment, over all meals); body weight; body
mass index (BMI) and waist circumference; fasting blood lipid levels
(free fatty acids [FFAs], total cholesterol, HDL cholesterol, LDL cho-
lesterol, VLDL cholesterol and triglycerides); and systolic and diastolic
blood pressure (BP). Other efficacy endpoints included the proportion
of participants reaching HbA1c targets of ≤6.5% (American
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Association of Clinical Endocrinologists [AACE]),21 <7.0% (American
Diabetes Association [ADA] and Japan Diabetes Society [JDS])22,23
and <7.0% without severe or BG-confirmed symptomatic hypoglycae-
mia (defined as an episode that was severe according to ADA classifi-
cation22 or BG-confirmed by plasma glucose <3.1 mmol/L, with
symptoms consistent with hypoglycaemia) and no weight gain, and
proportion of participants achieving weight loss of ≥5% or ≥10% at
week 30.
Supportive secondary safety endpoints included: the number of
treatment-emergent severe or BG-confirmed symptomatic hypogly-
caemic episodes during 30 weeks of treatment; change from baseline
to week 30 in laboratory and physical examination variables; and
occurrence of anti-semaglutide antibodies. An external Event Adjudi-
cation Committee (EAC) validated selected adverse events (AEs),
according to predefined diagnostic criteria, in an independent, blinded
manner (Table S2). Events were adjudicated according to Food and
Drug Administration guidance and requirements.
2.6 | Statistical analysis
Trial sample size was determined based on the “Guideline for Clinical
Evaluation of Oral Hypoglycaemic Agents.”18 With the planned num-
ber of randomized participants of 306, a total of 81 participants ran-
domized to each group were expected to complete treatment,
assuming a treatment discontinuation rate of 20%. Together with the
other trials in the SUSTAIN programme, ≥300 Japanese participants
were expected to complete ≥6 months of treatment with semaglutide
monotherapy.
Randomized participants receiving at least 1 dose of trial product
comprised the full analysis set and the safety analysis set.
A TEAE was defined as an event with onset from first exposure
to the follow-up visit scheduled 5 weeks (+1 week visit window)
after the last trial product dose.
Main efficacy evaluations were based on assessments collected
in the period where participants were treated with trial product, with-
out rescue medication (“on-treatment without rescue medication”
period). Supportive analyses of efficacy and safety were based on
assessments collected in the period where participants, after random-
ization, were considered trial participants and where data were to be
collected systematically (“in-trial” period). Continuous efficacy end-
points assessed over time were analysed using a mixed model for
repeated measurements (MMRM) with treatment and pre-trial treat-
ment at screening as fixed factors and baseline value as a covariate,
all nested within visits. With the exception of HbA1c, body weight,
FPG, SMPG, BMI, waist circumference and BP, values were log-
transformed before analysis. Efficacy continuous endpoints assessed
at baseline and week 30 were analysed using an analysis of covari-
ance (ANCOVA) model. For the HbA1c target endpoints (<7% and
≤6.5%) and weight loss response endpoints (≥5% and ≥10%), missing
data at week 30 were imputed from the MMRM, used for the corre-
sponding continuous endpoint, and subsequently classified. Treat-
ment comparison was based on a logistic regression model including
the same fixed factors and associated baseline value(s) as covariate,
except for the weight-loss response of ≥10%, which was compared
using a Fisher’s exact test, as no participants achieved this response
in the sitagliptin group.
The sensitivity of the main results of HbA1c and body weight
was assessed using complete case analyses (MMRM-based),
ANCOVA using the last observation carried forward (LOCF) imputa-
tion, and comparator-based multiple imputation.
Data collected throughout the trial, regardless of whether partici-
pants discontinued treatment prematurely or initiated rescue medica-
tion, were also analysed (“in-trial” analysis; MMRM based); thus, the
amount of missing data was expected to be small.
3 | RESULTS
3.1 | Participant disposition and baseline
characteristics
In total, 308 adults with T2D were randomized to receive 1 of the
2 semaglutide maintenance doses or sitagliptin, all of whom were
exposed to trial product (Figure 1). A higher proportion of partici-
pants discontinued treatment prematurely in the semaglutide 1.0 mg
group (14.7%) compared with the semaglutide 0.5 mg and sitagliptin
groups (each 2.9%). All semaglutide 0.5 mg-treated participants com-
pleted the trial, whereas 3 participants in the semaglutide 1.0 mg
group and 2 in the sitagliptin group withdrew prematurely. Rescue
medication was provided to 1 participant in the semaglutide 0.5 mg
group and 5 participants in the sitagliptin group.
Baseline characteristics were generally well balanced between
the three groups (Table 1). The majority (76.3%) of participants were
men, mean HbA1c was 8.1%, mean diabetes duration was 8.0 years,
and the proportion of participants randomized while on pre-trial OAD
treatment was 29.9%. Mean body weight was 69.3 kg, although par-
ticipants in the semaglutide 1.0 mg group were 3.0 kg heavier than in
the semaglutide 0.5 mg group (70.8 vs 67.8 kg).
3.2 | Primary endpoint
Overall, the proportion of participants reporting TEAEs during the
trial (primary endpoint) was higher with semaglutide (0.5 mg: 74.8%;
1.0 mg: 71.6%) than with sitagliptin (66.0%) (Table 2). AEs were
mainly mild or moderate in severity (Table 2). The proportion of parti-
cipants discontinuing treatment because of AEs was relatively low for
semaglutide 0.5 mg and sitagliptin (2.9% and 1.9%, respectively), but
higher for semaglutide 1.0 mg (10.8%) (Figure S2). Serious AEs (SAEs)
were reported by 5.8%, 2.0% and 1.9% of participants treated with
semaglutide 0.5 mg, 1.0 mg and sitagliptin, respectively. Events were
distributed among multiple system organ classes, with no clustering
(Table S3). No deaths were reported in the trial (Table 2).
The most frequently reported AEs were gastrointestinal
(GI) events; namely constipation (14.6% and 11.8% for semaglutide
0.5 and 1.0 mg, respectively, vs 3.9% with sitagliptin), nausea (10.7%
and 12.7%, vs none with sitagliptin) and diarrhoea (6.8% and 8.8%, vs
1.9% with sitagliptin; Table S4). GI events diminished over time
(Figure S3).
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3.3 | Secondary efficacy endpoints
3.3.1 | Glycaemic control
At week 30, mean HbA1c (baseline 8.1%) decreased by 1.9% and
2.2% with semaglutide 0.5 and 1.0 mg, respectively, vs 0.7% with
sitagliptin (estimated treatment difference [ETD] vs sitagliptin
−1.13%, 95% confidence interval [CI] −1.32; −0.94 and −1.44%, 95%
CI −1.63; −1.24; both P < .0001 [Figure 2A,B and Table 3]). Statistical
sensitivity analyses for change in HbA1c at week 30 supported the
main analysis result (Figure S4A). The cumulative distribution of
changes in HbA1c from baseline to week 30 indicated that greater
proportions of participants treated with semaglutide 0.5 and 1.0 mg
achieved improvements in glycaemic control compared with
sitagliptin-treated participants; nearly all participants treated with
semaglutide attained improvements in glycaemic control (Figure S5A).
At week 30, the ADA- and JDS-defined target (HbA1c <7.0%)
was achieved by 84% and 95% of 0.5 and 1.0 mg semaglutide-
treated participants, respectively, vs 35% in the sitagliptin group
(both P < .0001). At week 30, the AACE target (HbA1c ≤6.5%) was
achieved by 71% and 87% of 0.5 and 1.0 mg semaglutide-treated
participants, respectively, vs 16% in the sitagliptin group (both
P < .0001; Figure 2C,D and Table 3). Similarly, the proportion of
FIGURE 1 Flow of participants through the trial. Numbers in brackets within treatment discontinuation category denote subjects who also
withdrew from trial, as those who discontinued treatment had the option to continue follow-up. Trial completers were participants who were
exposed, did not withdraw from trial and who attended a follow-up
TABLE 1 Baseline characteristics of trial populations
Semaglutide 0.5 mg Semaglutide 1.0 mg Sitagliptin 100 mg Total
Mean s.d. Mean s.d. Mean s.d. Mean s.d.
Age, years 58.8 10.4 58.1 11.6 57.9 10.1 58.3 10.7
Male/female, % 76.7/23.3 - 73.5/26.5 - 78.6/21.4 - 76.3/23.7 -
HbA1c, % 8.2 1.0 8.0 0.9 8.2 0.9 8.1 0.9
FPG, mmol/L 9.2 2.1 9.2 1.8 9.5 2.0 9.3 2.0
Diabetes duration, years 8.0 5.2 7.8 6.9 8.1 6.7 8.0 6.3
Body weight, kg 67.8 11.7 70.8 16.4 69.4 12.9 69.3 13.8
BMI, kg/m2 25.1 3.8 26.1 5.2 25.1 3.6 25.4 4.3
Previously treated with:
Diet and exercise therapy, % 69.9 - 70.6 - 69.9 - 70.1 -
OAD therapy, % 30.1 - 29.4 - 30.1 - 29.9 -
Biguanides 11.7 - 12.7 - 11.7 - 12.0 -
SU 4.9 - 2.0 - 4.9 - 3.9 -
α-GI 1.9 - 2.9 - 1.9 - 2.3 -
TZDs 1.9 - 2.0 - 2.9 - 2.3 -
DPP-4 inhibitors 7.8 - 6.9 - 5.8 - 6.8 -
Other BG-lowering drugsa 1.9 - 2.9 - 2.9 - 2.6 -
Abbreviations: α-GI, α-glucosidase inhibitor; BG, blood glucose; BMI, body mass index; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtra-
tion rate; FPG, fasting plasma glucose; OAD, oral antidiabetic drug; s.d., standard deviation; SU, sulphonylurea; TZD, thiazolidinedione.
a Excluding insulin. Summary is based on the full analysis set.
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participants achieving HbA1c <7.0% with no severe or BG-confirmed
symptomatic hypoglycaemia and no weight gain at week 30 was
greater with semaglutide than with sitagliptin (72% and 84% vs 18%,
respectively; P < .0001 for both; Figure 2E and Table 3).
Reductions in mean FPG were significantly greater with semaglu-
tide than with sitagliptin: 2.8 and 3.3 mmol/L with semaglutide 0.5
and 1.0 mg, respectively, vs 1.3 mmol/L with sitagliptin (ETD
−1.47 mmol/L [95% CI −1.78; −1.16] and −1.99 mmol/L [95% CI
−2.30; −1.67], respectively; both P < .0001).
Mean 7-point SMPG values significantly decreased with both
semaglutide doses vs sitagliptin (ETD −1.66 mmol/L [95% CI −2.09;
−1.23] and −2.24 mmol/L [95% CI −2.68; −1.80], respectively; both
P < .0001). Similarly, there was a significant reduction in the SMPG
postprandial increment with semaglutide vs sitagliptin (ETD
−0.78 mmol/L [95% CI −1.27; −0.29] and −1.44 mmol/L [95% CI
−1.95; −0.94], respectively; P = .0020 and P < .0001).
3.3.2 | Body weight
At week 30, body weight (baseline 69.3 kg) was reduced by 2.2 and
3.9 kg with semaglutide 0.5 and 1.0 mg, respectively, vs no reduction
with sitagliptin (ETD −2.22 kg, 95% CI −3.02; −1.42, and −3.88 kg,
95% CI −4.70; −3.07; both P < .0001 [Figure 2F and G and Table 3]).
Sensitivity analyses for change in body weight at week 30 supported
the main analysis result (Figure S4B). The cumulative distribution of
changes in body weight from baseline to week 30 indicated that
greater proportions of participants treated with semaglutide 0.5 and
1.0 mg achieved reductions in weight compared with sitagliptin-
treated participants; most semaglutide-treated participants achieved
weight loss (Figure S5B).
A weight loss of ≥5% was achieved by 29% and 57% of 0.5 and
1.0 mg semaglutide-treated participants, respectively, vs 7% in the sita-
gliptin group (P < .0002 and P < .0001, respectively). A weight loss of
≥10% was achieved by 7% and 19% of 0.5 and 1.0 mg semaglutide-
treated participants, respectively, vs 0% in the sitagliptin group
(P .0141 and P < .0001, respectively) (Figure 2H and I, and Table 3).
3.3.3 | Other efficacy endpoints
Treatment with semaglutide 0.5 and 1.0 mg reduced BMI and waist
circumference, compared with sitagliptin (P < .0001 for both). In
addition, decreases in BP were generally greater with semaglutide
1.0 mg than with sitagliptin. The difference in systolic BP with sema-
glutide 1.0 mg, vs sitagliptin, was significant (ETD −6.01 mmHg, 95%
CI −9.16; −2.85; P = .0002); there was no significant difference in
diastolic BP (Table 3).
Total cholesterol and LDL cholesterol were significantly reduced
with both semaglutide doses, whereas VLDL cholesterol and triglycer-
ides were significantly reduced with semaglutide 1.0 mg vs sitagliptin.
There was no significant difference in change in HDL cholesterol or
FFA levels between semaglutide and sitagliptin (Figure S6).
3.4 | Supportive secondary safety endpoints
No severe episodes of hypoglycaemia were reported in any treatment
group. One hypoglycaemic episode, classified as “severe or BG-
confirmed symptomatic,” was reported in the semaglutide 1.0 mg
group (Table S5). This event was symptomatic and plasma glucose
level was 2.6 mmol/L.
No EAC-confirmed pancreatitis events were reported. Mean
levels of pancreatic enzymes (lipase and amylase) increased for both
semaglutide doses vs sitagliptin. One participant treated with sema-
glutide 1.0 mg experienced cholelithiasis (Table S5), which did not
lead to premature treatment discontinuation. There were 2 EAC-
confirmed cardiovascular events in the semaglutide 0.5 mg group
(Table S5; 1 event of silent myocardial infarction; 1 of percutaneous
revascularization).
Pulse (baseline 71.9 bpm) increased in all 3 groups (ETD
3.41 bpm [95% CI 1.22; 5.59] and 4.94 bpm [95% CI 2.69; 7.19] for
semaglutide 0.5 and 1.0 mg vs sitagliptin, respectively; P = .0024 and
P < .0001 [Table 3]).
Overall, 2 EAC-confirmed malignant neoplasms were reported;
1 with semaglutide 1.0 mg (malignant low-grade bladder cancer
tumour) and 1 with sitagliptin (malignant pancreatic carcinoma stage
IV). The participant in the semaglutide 1.0 mg arm completed
treatment; the sitagliptin-treated participant discontinued treatment.
No malignant neoplasms were reported with semaglutide 0.5 mg
(Table S5). No EAC-confirmed thyroid neoplasms or medullary thyroid
carcinomas were reported. Calcitonin levels were similar between
groups with no apparent change during the trial.
TABLE 2 Treatment-emergent adverse events overview
Semaglutide 0.5 mg Semaglutide 1.0 mg Sitagliptin 100 mg
N (%) E R N (%) E R N (%) E R
Number of participants 103 102 103
AEs: total 77 (74.8) 228 331.8 73 (71.6) 197 312.6 68 (66.0) 186 267.4
Fatal 0 - - - 0 - - - 0 - - -
Serious 6 (5.8) 7 10.2 2 (2.0) 2 3.2 2 (1.9) 3 4.3
Severity of AEs
Severe 2 (1.9) 2 2.9 1 (1.0) 1 1.6 2 (1.9) 5 7.2
Moderate 13 (12.6) 23 33.5 9 (8.8) 12 19.0 10 (9.7) 10 14.4
Mild 73 (70.9) 203 295.4 68 (66.7) 184 292.0 67 (65.0) 171 245.8
Leading to premature treatment discontinuation 3 (2.9) 5 7.3 11 (10.8) 15 23.8 2 (1.9) 4 5.8
Abbreviations: E, number of events; N, number of participants experiencing at least one event; R, event rate per 100 years of exposure.
TEAEs include events with onset from first exposure to the follow-up visit scheduled 5 weeks (+1 week visit window) after the last trial product dose.
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Nervous system disorders were reported by 12 participants
(11.7%) in the semaglutide 0.5 mg group, none in the semaglutide
1.0 mg group and 5 (4.9%) in the sitagliptin group (Table S5), and
were composed of single unrelated AEs.
One semaglutide 1.0 mg-treated participant developed anti-
semaglutide antibodies; however, there was no cross-reaction with
endogenous GLP-1. At follow-up, the participant tested antibody-
negative and therefore no in vitro neutralizing effect was assessed.
There were 4 reported events of diabetic retinopathy in the
semaglutide 0.5 mg group, 2 events in the semaglutide 1.0 mg group,
and 4 events in the sitagliptin group.
There were no clinically relevant changes in other safety labora-
tory assessments, physical examinations or electrocardiograms.
4 | DISCUSSION
The results of the present trial showed that, in Japanese participants
with T2D, more participants receiving semaglutide reported TEAEs
than with sitagliptin. This was driven mainly by GI AEs, a well-known
side effect of GLP-1 RAs. The discontinuation rate was low and simi-
lar between semaglutide 0.5 mg and sitagliptin, but was higher with
semaglutide 1.0 mg, owing to a larger proportion of participants
experiencing GI AEs. The slightly higher rate of constipation vs nau-
sea and diarrhoea than reported in global trials may have been influ-
enced by other factors, such as differences in diet, cultural
differences in how constipation is defined or reported, or AE-
reporting bias among participants. The frequency of GI AEs
FIGURE 2 Efficacy variables. Semaglutide 0.5 mg once weekly and 1.0 mg once weekly, compared with sitagliptin 100 mg once daily: mean
HbA1c over time (A); change in mean HbA1c after 30 weeks (B); proportion of participants achieving HbA1c < 7.0% at 30 weeks (C); proportion
of participants achieving HbA1c ≤ 6.5% at 30 weeks (D); proportion of participants achieving HbA1c < 7.0% with no severe or BG-confirmed
symptomatic hypoglycaemia and no weight gain at week 30 (E); mean body weight over time (F); change in mean body weight after 30 weeks
(G); proportion of participants achieving ≥5% (H) or ≥10% (I) weight loss after 30 weeks. *Indicates significance (P < .0001); †indicates
significance (P < .05). Values in A, B, F and G are estimated mean ( standard errors) from a MMRM using “on-treatment without rescue
medication” data from subjects in the full analysis set. Dotted line in A and F is the overall mean value at baseline. Values in C, D, H and I are
proportions using “on-treatment without rescue medication” data from subjects in the full analysis set. Missing data are imputed from a MMRM
and subsequently classified.
Abbreviations: BG, confirmed; BG <3.1 mmol/L; MMRM, mixed model for repeated measurements; OR, odds ratio.
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diminished over time, as observed with other GLP-1 RAs and other
studies with semaglutide.10–15,24,25 Dose escalation of GLP-1 RAs has
also previously been shown to partially ameliorate GI AEs, as
reflected in the design of this trial.26
In general, the AE profile of semaglutide was similar to that of
other GLP-1 RAs5; for example, in addition to GI AEs, a commonly
reported TEAE was increased levels of pancreatic enzymes for both
semaglutide doses vs sitagliptin (although no pancreatitis events were
reported). Pancreatitis cases have previously been reported in
exenatide-treated patients and in other clinical development pro-
grammes for GLP-1 RAs and other incretin-based drugs,27,28 although
retrospective analyses suggest there is no increased risk of acute
cases.29–32 In addition, reduced appetite was frequently reported in
semaglutide-treated participants. This is a class effect, as GLP-1
receptors are expressed in the hypothalamus, the region of the brain
that regulates satiety and appetite. Effectively, this is thought to be
the mechanism that enables GLP-1 RAs to lower energy intake,
thereby reducing body weight,33,34 although to a varying degree. The
increase in pulse rate reported with semaglutide treatment has also
been previously reported in, for example, liraglutide- and exenatide-
treated participants,24,35 although the potential mechanisms behind
this haemodynamic effect are unclear.36
Compared with sitagliptin 100 mg monotherapy, both semaglu-
tide 0.5 and 1.0 mg monotherapy significantly improved glycaemic
control (change in HbA1c: −1.9%, −2.2% vs −0.7%, respectively)
and reduced body weight (−2.2 kg, −3.9 kg vs 0.0 kg, respectively).
These improvements were sustained over 30 weeks of treatment,
and were supported by the sensitivity analyses. Furthermore, sig-
nificantly greater proportions of participants receiving semaglutide
achieved the ADA and JDS target of HbA1c <7.0% vs sitagliptin
(84% and 95% of 0.5 and 1.0 mg semaglutide-treated participants,
respectively, vs 35% in the sitagliptin group). Importantly, a higher
proportion of participants treated with semaglutide than with sita-
gliptin achieved this target with no severe or BG-confirmed symp-
tomatic hypoglycaemia and no weight gain at week 30 (72% and
84% vs 18%, respectively). Semaglutide’s efficacy relating to body
weight was also evident compared with sitagliptin, with greater
proportions of participants achieving body weight loss of ≥5%
(29% and 57% vs 7%, respectively) and ≥10% (7% and 19% vs 0%,
respectively).
These findings are consistent with the global SUSTAIN trials, in
which semaglutide was associated with clinically meaningful and
superior reductions in HbA1c and body weight vs placebo (SUSTAIN
1 and SUSTAIN 5 [add-on to insulin]),10,14 sitagliptin (SUSTAIN 2)11 –
all multinational trials that included Japan, exenatide ER (SUSTAIN
3),12 and insulin glargine (SUSTAIN 4).13 The findings also align with
trials of liraglutide in participants with T2D, where significant reduc-
tions in HbA1c and body weight were observed, either compared
with placebo or a thiazolidinedione, all when added to a sulphony-
lurea24; or compared with placebo or a sulphonylurea, all on a back-
ground of metformin.25 In addition, similar results have been
observed with other GLP-1 RAs, such as albiglutide37 and
dulaglutide,38 either compared with placebo or active comparators
such as sitagliptin or insulin glargine, as monotherapy or add-on ther-
apy to other antidiabetic agents.
In the present trial, semaglutide also resulted in marked improve-
ments in cardiometabolic risk compared with sitagliptin, and included
reductions in BMI, waist circumference and BP, and improvements in
most lipid level profiles. In SUSTAIN 6, semaglutide was associated
with a significant 26% reduction in cardiovascular risk (primary com-
posite outcome of death from cardiovascular causes, non-fatal myo-
cardial infarction or non-fatal stroke) compared with placebo in a
standard-of-care setting.15
Baseline characteristics, although similar across the 3 treatment
groups, differed slightly from the global SUSTAIN trials. In this trial
population, baseline body weight and BMI were markedly lower than
in participants from various ethnic groups in the global trials, reflect-
ing an overall leaner population.
Furthermore, more marked reductions in HbA1c were reported
in this trial than in the SUSTAIN 1 to 5 trials.10–14 The reasons for
this difference between the present trial and SUSTAIN 1 to 5 are
unclear; however, these results are in line with a recent meta-analysis
in which GLP-1 analogues were associated with greater HbA1c
reductions and a higher proportion of participants achieving HbA1c
target ≤7% in Asian (including Japanese) vs non-Asian populations.39
Participants in this trial had a mean baseline diabetes duration of
8.0 years, similar to the global SUSTAIN 2 trial (6.6 years), but early
initiation of treatment may be beneficial in Asian people to provide
sustained glycaemic control and avoid long-term diabetes complica-
tions. Although body weight was reduced with semaglutide in this
trial, greater reductions were reported in the SUSTAIN 1 to 5 trials
(3.5–4.3 kg with semaglutide 0.5 mg; 4.5–6.4 kg with semaglutide
1.0 mg).10–14 Both baseline body weight and BMI were lower in this
trial population, by ~20 kg and 7 kg/m2, respectively; thus, the body
weight reductions of 3.3% and 5.7% with semaglutide 0.5 and
1.0 mg, respectively, should be considered in this context. It might be
expected that Japanese participants would lose less body mass over-
all than a heavier and/or obese cohort, as ~80% of weight lost with
semaglutide treatment is fat mass.40 This, together with the influence
of the Japanese diet, may have affected the overall change in body
weight in this trial.
These efficacy results might also be considered in the context
that, in East Asia, T2D is characterized by significant β-cell dysfunc-
tion with less adiposity and less insulin resistance than in Western
populations. Consequently, incretin-based drugs may show more effi-
cacy in Asian populations, mostly because of amelioration of β-cell
dysfunction.41,42
The open-label design of this trial is a limitation, increasing the
risk of bias. The relatively short trial duration is also a limitation, as
the full potential of semaglutide with regard to durability, efficacy
and safety may not have been observed over 30 weeks. In addition,
approximately three-quarters of the total trial population was male
and, as such, may not accurately reflect the T2D population in Japan.
Differential results between men and women with T2D, however,
would not be expected. Furthermore, the authors acknowledge that
GLP-1 RAs are not usually considered for monotherapy; neither is
sitagliptin the most frequently used monotherapeutic oral agent in
Japan. Thus, in clinical practice, both semaglutide and sitagliptin
would probably be given in combination with metformin, and the
applicability of the results should be interpreted in this context,
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whereby the treatment regimens described may not reflect main-
stream practice in the T2D population in Japan. Nevertheless, the
SUSTAIN programme as a whole covered a broad spectrum of
patients with T2D10–17; for example, SUSTAIN 2, which included
patients from Japan, investigated semaglutide vs sitagliptin as an add-
on to metformin.11 It should be noted that, in line with regulatory
requirements, this trial was designed to assess these treatments as
monotherapy, in order to investigate the safety and efficacy of each
in isolation. Finally, the collection of body composition data would
have been useful, to clarify whether the observed body weight loss
with semaglutide was caused by loss of fat or lean body mass. A
recently published study involving semaglutide treatment in obese
participants has, however, demonstrated that semaglutide is associ-
ated with a 3-fold greater loss of fat over lean body mass compared
with placebo.40
Despite these limitations, the significant reductions in HbA1c
and body weight observed in this trial indicate the potential for sema-
glutide as a treatment option in Japanese participants with T2D. This
is important given that many other treatments are either weight-
neutral or associated with weight gain.43–45
In conclusion, in Japanese participants with T2D, more TEAEs
were reported with semaglutide (0.5 and 1.0 mg) than with sitagliptin,
but semaglutide was well tolerated, with a safety profile similar to
that of other GLP-1 RAs. Semaglutide had a greater effect on glycae-
mic control, body weight reduction and other efficacy variables vs
sitagliptin 100 mg monotherapy.
ACKNOWLEDGMENTS
We thank all the participants, investigators and trial-site staff who
were involved in the conduct of the trial. We also thank Sayeh
Tadayon and Hrvoje Vrazic (Novo Nordisk) for their review and input
to the manuscript, and Sola Neunie, MSc, CMPP (AXON Communica-
tions) for medical writing and editorial assistance, who received com-
pensation from Novo Nordisk.
Conflict of interest
Y.S. has received honoraria for consulting and/or speakers bureau
from Kao; Kyowa Hakko Kirin; Taisho Pharmaceutical; Becton, Dick-
inson and Company; Novo Nordisk; MSD; Intarcia Therapeutics;
Johnson & Johnson; GlaxoSmithKline; Takeda Pharmaceutical Com-
pany; Sanofi; Taisho Toyama Pharmaceutical; Eli Lilly & Company;
Mitsubishi Tanabe Pharma; Ono Pharmaceutical; Kowa; Astellas
Pharma; Boehringer Ingelheim; AstraZeneca; Sumitomo Dainippon
Pharma; Daiichi Sankyo; Terumo; Arkray; and clinical commissioned/
joint research grants from Arkray Marketing; Kowa; Hayashibara;
Nippon Boehringer Ingelheim; Eli Lilly & Company; Terumo; Taisho
Toyama Pharmaceutical; MSD K.K.; Ono Pharmaceutical; Novo Nor-
disk; Sumitomo Dainippon Pharma; Arklay. Y. T. has received honor-
aria for speakers bureau from Astellas Pharma; AstraZeneca K.K.;
Bayer Yakuhin; Daiichi Sankyo; Sumitomo Dainippon Pharma; Eli Lilly
Japan K.K.; Kowa; MSD K.K.; Mitsubishi Tanabe Pharma; Nippon
Boehringer Ingelheim; Novo Nordisk; Ono Pharmaceutical; Sanwa
Kagaku Kenkyusho; Sanofi K.K.; Shionogi & Company; Taisho
Toyama Pharmaceutical; Takeda Pharmaceutical Company; and grants
from Astellas Pharma; AstraZeneca K.K.; Bayer Yakuhin; Daiichi San-
kyo; Sumitomo Dainippon Pharma; Eli Lilly Japan K.K.; Kowa; MSD
K.K.; Mitsubishi Tanabe Pharma; Nippon Boehringer Ingelheim; Novo
Nordisk; Ono Pharmaceutical; Pfizer Japan; Sanwa Kagaku Ken-
kyusho; Sanofi K.K., Shionogi & Company; Takeda Pharmaceutical
Company. T. O. is a lecturer and clinical study investigator for Novo
Nordisk. D. Y. has received consulting and/or speaker fees from MSD
K.K.; Novo Nordisk; Takeda Pharmaceutical Company; Taisho
Toyama Pharmaceutical; and clinical commissioned/joint research
grants from Nippon Boehringer Ingelheim; Eli Lilly & Company;
Taisho Toyama Pharmaceutical; MSD K.K.; Ono Pharmaceutical;
Novo Nordisk; Arklay; Takeda Pharmaceutical Company. NA has no
conflicts of interest. T.N. is an employee of Novo Nordisk and holds
shares in the company. J. Z. is an employee of Novo Nordisk and
holds shares in the company. S. K. has received honoraria for speak-
ers bureau from Astellas Pharma; AstraZeneca K.K.; Daiichi Sankyo;
Sumitomo Dainippon Pharma; Eli Lilly Japan K.K.; Kissei Pharmaceuti-
cal; Mitsubishi Tanabe Pharma; Novo Nordisk; Novartis Pharma K.K.;
Ono Pharmaceutical; Sanofi K.K.; Taisho Toyama Pharmaceutical;
Takeda Pharmaceutical Company; and grants from WebMD
Global LLC.
Author contributions
Y.S.: study design, study conduct/data collection, writing the manu-
script; Y.T.: study conduct/data collection, data analysis, writing the
manuscript; T.O.: data collection; D.Y.: study conduct/data collection,
data analysis, writing the manuscript; N.A.: study conduct/data col-
lection, reviewing the manuscript; T.N.: study design, data analysis,
writing the manuscript; J.Z.: study design, study conduct/data collec-
tion, data analysis, writing the manuscript; S.K.: study conduct/data




1. Mukai N, Doi Y, Ninomiya T, et al. Trends in the prevalence of type
2 diabetes and prediabetes in community-dwelling Japanese subjects:
the Hisayama Study. J Diabetes Invest. 2014;5(2):162–169.
2. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC.
The prevalence of meeting A1c, blood pressure, and LDL goals
among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):
2271–2279.
3. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Asso-
ciation of Clinical Endocrinologists and American College of Endocri-
nology – clinical practice guidelines for developing a diabetes mellitus
comprehensive care plan – 2015. Endocr Pract. 2015;21(suppl
1):1–87.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hypergly-
cemia in type 2 diabetes, 2015: a patient-centered approach: update
to a position statement of the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetes Care.
2015;38(1):140–149.
5. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor ago-
nists: efficacy and safety in diabetes and beyond. Drugs Context.
2015;4:212283. https://doi.org/10.7573/dic.212283.
386 SEINO ET AL.
6. Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly
human GLP-1 analog, does not reduce the bioavailability of the com-
bined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Phar-
macol. 2015;55(5):497–504.
7. Marbury TC, Flint A, Segel S, Lindegaard M, Lasseter KC. Abstracts of
the 50th EASD Annual Meeting, September 15–19, 2014, Vienna,
Austria. Diabetologia. 2014;57(suppl 1):S358.
8. Inukai K, Hirata T, Sumita T, et al. Clinical characteristics of Japanese
type 2 diabetic patients responsive to sitagliptin. J Diabetes Mellitus.
2014;4:172–178.
9. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1: incretin actions beyond the pancreas.
J Diabetes Investig. 2013;4(2):108–130.
10. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-
weekly semaglutide monotherapy versus placebo in patients with
type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-
controlled, parallel-group, multinational, multicentre phase 3a trial.
Lancet Diabetes Endocrinol. 2017;5(4):251–260.
11. Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-
weekly, subcutaneous semaglutide versus oral sitagliptin as add-on to
metformin and/or thiazolidinediones in subjects with type 2 diabetes
(SUSTAIN 2): a 56-week randomised, controlled clinical trial. Lancet
Diabetes Endocrinol. 2017;5(5):341–354.
12. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of
once-weekly semaglutide vs exenatide ER after 56 weeks in subjects
with type 2 diabetes (SUSTAIN 3). American Diabetes Association –
76th Annual Scientific Sessions; New Orleans, LA, USA, 2016;65-
(suppl 1):A49.
13. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-
weekly semaglutide versus once-daily insulin glargine as add-on to
metformin (with or without sulphonylureas) in insulin-naive patients
with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-
group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endo-
crinol. 2017;5(5):355–366.
14. Rodbard H, Lingvay I, Reed J, et al. Efficacy and safety of semaglutide
once-weekly vs placebo as add-on to basal insulin alone or in combi-
nation with metformin in subjects with type 2 diabetes (SUSTAIN 5).
Diabetologia. 2016;59(suppl 1):S364–S365.
15. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular
outcomes in patients with type 2 diabetes. N Engl J Med.
2016;10(375):1834–1844.
16. ClinicialTrials.gov. A trial comparing the safety and efficacy of sema-
glutide once weekly in monotherapy or in combination with one
OAD in Japanese subjects with type 2 diabetes (SUSTAIN™). 2014.
https://clinicaltrials.gov/ct2/show/NCT02207374. Accessed Septem-
ber 20, 2017.
17. ClinicialTrials.gov. A trial comparing the safety and efficacy of sema-
glutide once weekly versus sitagliptin once daily in Japanese subjects
with type 2 diabetes (SUSTAIN™). 2014. https://clinicaltrials.gov/
ct2/show/NCT02254291. Accessed September 20, 2017.
18. Ministry of Health, Labour and Welfare. Guideline for Clinical Evalua-
tion of Oral Hypoglycaemic Agents. 2010. Pharmaceuticals and Medical
Devices Agency, Tokyo, Japan. https://www.pmda.go.jp/files/
000208194.pdf. Accessed September 20, 2017.
19. European Agency for the Evaluation of Medicinal Products. Interna-
tional Conference on Harmonisation-World Health Organization
guideline for good clinical practice [EMEA Web site] ICH harmonised
tripartite guideline good clinical practice. 2016. http://www.ema.
europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/
09/WC500002874.pdf. Accessed September 20, 2017.
20. World Medical Association. Declaration of Helsinki ethical principles
for medical research involving human subjects. Last amended by the
59th WMA General Assembly, Seoul, Republic of Korea. 2008.
https://www.wma.net/policies-post/wma-declaration-of-helsinki-
ethical-principles-for-medical-research-involving-human-subjects/.
Accessed September 20, 2017.
21. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by
the American Association of Clinical Endocrinologists and American
College of Endocrinology on the comprehensive type 2 diabetes man-
agement algorithm – 2017 executive summary. Endocr Pract.
2017;23:207–238.
22. American Diabetes Association. Standards of medical care in diabetes
– 2016. Diabetes Care. 2016;39(suppl 1):S1–S112.
23. The Japan Diabetes Society. Evidence-based practice guideline for
the treatment for diabetes in Japan 2013. http://www.jds.or.jp/
modules/en/index.php?content_id=44. Accessed September 20,
2017.
24. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human
GLP-1 analogue, added to a sulphonylurea over 26 weeks produces
greater improvements in glycaemic and weight control compared with
adding rosiglitazone or placebo in subjects with Type 2 diabetes
(LEAD-1 SU). Diabet Med. 2009;26(3):268–278.
25. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison
of liraglutide, glimepiride, and placebo, all in combination with metfor-
min, in type 2 diabetes: the LEAD (liraglutide effect and action in dia-
betes)-2 study. Diabetes Care. 2009;32(1):84–90.
26. Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-
finding study of the novel once-weekly human GLP-1 analog, sema-
glutide, compared with placebo and open-label liraglutide in patients
with type 2 diabetes. Diabetes Care. 2016;39(2):231–241.
27. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J
Med. 2008;358(18):1970–1971.
28. Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety con-
sideration in the decision making process for selecting a second medi-
cation for type 2 diabetes management. Reflections from a diabetes
care editors' expert forum. Diabetes Care. 2014;37(9): 2647–2659.
29. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes
treated with exenatide or sitagliptin: a retrospective observational
pharmacy claims analysis. Diabetes Care. 2010;33(11):2349–2354.
30. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug
safety surveillance system to assess the risk of acute pancreatitis with
exenatide or sitagliptin compared to metformin or glyburide. Curr
Med Res Opin. 2009;25(4):1019–1027.
31. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute
pancreatitis in relation to exenatide use. Diabetes Obes Metab.
2011;13(6):559–566.
32. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pan-
creatitis in initiators of exenatide twice daily compared with other
antidiabetic medication: a follow-up study. Diabet Med. 2012;29(11):
1412–1418.
33. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes
satiety and suppresses energy intake in humans. J Clin Invest. 1998;
101(3):515–520.
34. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates
GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin
Invest. 2014;124(10):4473–4488.
35. Kothare PA, Linnebjerg H, Isaka Y, et al. Pharmacokinetics, pharmaco-
dynamics, tolerability, and safety of exenatide in Japanese patients
with type 2 diabetes mellitus. J Clin Pharmacol. 2008;48(12):
1389–1399.
36. Gustavson SM, Chen D, Somayaji V, et al. Effects of a long-acting
GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pres-
sure in patients with type 2 diabetes mellitus. Diabetes Obes Metab.
2011;13(11):1056–1058.
37. Blair HA, Keating GM. Albiglutide: a review of its use in patients with
type 2 diabetes mellitus. Drugs. 2015;75(6):651–663.
38. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT.
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes:
a comprehensive review of the dulaglutide clinical data focusing on
the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev.
2016;32(8):776–790.
39. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-
lowering efficacy of glucagon-like peptide-1 analogues between
Asians and non-Asians: a systematic review and meta-analysis. Diabe-
tes Obes Metab. 2014;16(10):900–909.
40. Blundell J, Finlayson G, Buhl Axelsen M, et al. Effects of once-weekly
semaglutide on appetite, energy intake, control of eating, food prefer-
ence and body weight in subjects with obesity. Diabetes Obes Metab.
2017;19(9):1242–1251.
41. Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes:
focus on East Asian perspectives. J Diabetes Investig. 2016;7(suppl 1):
102–109.
SEINO ET AL. 387
42. Yabe D, Seino Y. Type 2 diabetes via β-cell dysfunction in East Asian
people. Lancet Diabetes Endocrinol. 2016;4(1):2–3.
43. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Inves-
tigators. The treat-to-target trial: randomized addition of glargine or
human NPH insulin to oral therapy of type 2 diabetic patients. Diabe-
tes Care. 2003;26(11):3080–3086.
44. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosigli-
tazone, metformin, or glyburide monotherapy. N Engl J Med.
2006;355(23):2427–2443.
45. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-
glucose control with sulphonylureas or insulin compared with con-
ventional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS)
Group. Lancet. 1998;352(9131):837–853.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: Seino Y, Terauchi Y, Osonoi T et al.
Safety and efficacy of semaglutide once weekly vs sitagliptin
once daily as monotherapy in Japanese people with type 2 dia-
betes. Diabetes Obes Metab. 2018;20:378–388. https://doi.
org/10.1111/dom.13082
388 SEINO ET AL.
